Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Viloxazine

Blesson M. Mathew  1 , Mark V. Pellegrini
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Viloxazine

Blesson M. Mathew et al.
Free Books & Documents

Excerpt

Viloxazine was marketed as an antidepressant in Europe for more than 2 decades under an immediate-release formulation before its potential as a treatment for patients with attention-deficit hyperactivity disorder (ADHD) was considered. Viloxazine received its first endorsement in the United Kingdom in 1971 and was subsequently recognized as an antidepressant in several other nations. However, commercial reasons led to its discontinuation in 2002.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Blesson Mathew declares no relevant financial relationships with ineligible companies.

Disclosure: Mark Pellegrini declares no relevant financial relationships with ineligible companies.

References

    1. Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH. Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021 Jun;35(6):643-653. - PMC - PubMed
    1. Nasser A, Hull JT, Liranso T, Busse GD, Melyan Z, Childress AC, A Lopez F, Rubin J. The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials. Neuropsychiatr Dis Treat. 2021;17:1751-1762. - PMC - PubMed
    1. Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020;12:285-300. - PMC - PubMed
    1. Lippman W, Pugsley TA. Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities. Can J Physiol Pharmacol. 1976 Aug;54(4):494-509. - PubMed
    1. Hafeez S, Saquib J, Qureshi NE. Viloxazine: A new miracle drug for attention deficit hyperactivity disorder (ADHD) or just another non-stimulant? Asian J Psychiatr. 2022 Jan;67:102948. - PubMed

Publication types

LinkOut - more resources